What to Expect From ResMed's Next Quarterly Earnings Report

Core Insights - ResMed Inc. is set to announce its fiscal Q1 earnings for 2026, with a current market cap of $41.1 billion [1] Financial Performance - Analysts anticipate a profit of $2.49 per share for the upcoming quarter, reflecting a 13.2% increase from $2.20 per share in the same quarter last year [2] - For fiscal 2026, expected profit is projected at $10.80 per share, a 13.1% rise from $9.55 per share in fiscal 2025, with further growth to $11.64 per share in fiscal 2027 [3] Stock Performance - ResMed's shares have increased by 20.3% over the past 52 weeks, outperforming the S&P 500 Index's 17.2% gain and the Health Care Select Sector SPDR Fund's 5% decline [4] Recent Developments - The company reported better-than-expected Q4 results, with revenue growing 10.2% year-over-year to $1.3 billion, exceeding consensus expectations by 2.3% [5] - Adjusted EPS for Q4 was $2.55, a 22.6% increase from the previous year, surpassing analyst estimates by 3.7% [5] Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for ResMed, with 17 analysts providing coverage: 8 recommend "Strong Buy," 2 suggest "Moderate Buy," 6 indicate "Hold," and 1 advises "Strong Sell" [6] - The mean price target for ResMed is $290.92, indicating a potential upside of 3.4% from current levels [6]